Bipolar disorder is a recurring chronic disorder characterized by state oscillations mood and energy and affects the daily life and functioning of the individual. It is one of the main causes of disability in young people leading to cognitive and functional impairment, increases mortality, especially death by suicide. Lithium is the gold standard in the treatment of bipolar disorder, however, it is not effective in all subtypes. The use of long-acting injections of antipsychotics as mood stabilizers in these patients could positively affect the patient's therapeutic response and adherence. Objectives The aim of this paper is to make a systematic review of the results of clinical trials conducted so far about the impact of long-acting antipsychotic injections on the treatment of bipolar disorder. Material/patients and methods Scientific and professional literature, publications of professional institutions (FDA, EFSA) were searched. Key database search words (Pubmed, ScienceDirect) included the following terms: adherence, antipsychotics, bipolar disorder, lithium, long acting. A review of the literature identified the possible impact of long-acting antipsychotics on the therapeutic response and adherence in bipolar disorder. Results These studies have shown that long-acting antipsychotics may improve adherence, reduce the risk of rehospitalization, the need for concomitant use of drugs to treat side effects, relapses of patients with a higher rate of recurrence and hospitalization, and with a greater number of manic symptoms. Conclusion Long-acting antipsychotics are an effective and well-tolerated therapy in the treatment of bipolar disorders, especially with manic predominant polarity and problems of nonadherence. Nevertheless, they are still not considered as possible first line in the treatment of bipolar disorder.